CryoPort To Provide Nohla Therapeutics With Cutting Edge Cold Chain Logistics To Support Clinical Programs
Published: Oct 02, 2017
IRVINE, Calif., Oct. 2, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Company"), the world's leading cryogenic logistics company dedicated to the life sciences industry, today announced that Cryoport will provide its leading edge cold chain logistics solutions to support Nohla Therapeutics' clinical studies evaluating its universal donor cell therapy, NLA101, in patients with hematologic malignancies and other critical diseases. Cryoport's solutions help companies increase their ability to supply product for clinical trials.
As a part of the agreement, Cryoport will provide global logistics support for Nohla's Phase 2 clinical trials, observing international best practices for transporting cryogenically preserved commodities. Cryoport's suite of unique cryogenic logistics solutions includes its Cryoport Express® shippers, SmartPak II Condition Monitoring System, Cryoportal Logistics Management Platform and 24/7/365 logistics support. These unparalleled capabilities enable Nohla to monitor its shipments and track the conditions and location of its biological commodities in transit around the clock, and to deploy intervention capability to mitigate any potential logistics risks.
Mr. Jerrell Shelton, Chief Executive Officer of Cryoport, Inc., commented, "Umbilical cord blood is known to be a useful source for blood stem cells and has been used to treat patients with certain blood diseases. Nohla Therapeutics is pioneering new universal donor off-the-shelf cord blood therapies designed to save lives, with a focus on individuals with hematologic malignancies, and we are proud that Nohla has selected Cryoport's advanced temperature controlled logistics solutions to support delivery of NLA101 to clinical trial sites. We look forward to working with Nohla and providing global logistics solutions."
Nohla is the leading developer of universal donor cell therapies for patients with hematologic malignances and other critical diseases. NLA101, the first product from Nohla's technology platform, is a regenerative cell therapy consisting of ex vivo expanded stem and progenitor cells derived from umbilical cord blood, available off the shelf without the need for HLA matching to the recipient. A randomized Phase 2 study is currently ongoing evaluating NLA101 in patients receiving a cord blood transplant. Nohla is also initiating a second randomized Phase 2 study evaluating NLA101 in acute myeloid leukemia (AML) patients at risk for myelosuppression following high-dose chemotherapy.
About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal Logistics Management Platform, leading-edge SmartPak II Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to
- simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;
- delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and
- providing vital information that provides peace of mind throughout the life of each logistics process.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the Company's cash flow, market acceptance risks, and technical development risks. The Company's business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the Transition Report on Form 10-K for the nine months ended December 31, 2016 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
SOURCE Cryoport, Inc.